These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22905596)
1. 3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Dominicus R Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):135-40. PubMed ID: 22905596 [TBL] [Abstract][Full Text] [Related]
2. Early improvement of patients' condition during allergen-specific subcutaneous immunotherapy with a high-dose hypoallergenic 6-grass pollen preparation. Rajakulasingam K Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):128-34. PubMed ID: 22905595 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885 [TBL] [Abstract][Full Text] [Related]
4. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570 [TBL] [Abstract][Full Text] [Related]
5. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541 [TBL] [Abstract][Full Text] [Related]
6. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Pfaar O; Robinson DS; Sager A; Emuzyte R Allergy; 2010 Dec; 65(12):1614-21. PubMed ID: 20645937 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Vervloet D; Birnbaum J; Laurent P; Hugues B; Fardeau MF; Massabie-Bouchat YP; Aferiat-Derome A; André C Int Arch Allergy Immunol; 2007; 142(3):239-46. PubMed ID: 17114889 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Frew AJ; Powell RJ; Corrigan CJ; Durham SR; J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Höiby AS; Strand V; Robinson DS; Sager A; Rak S Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579 [TBL] [Abstract][Full Text] [Related]
13. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study. Zidarn M; Košnik M; Šilar M; Bajrović N; Korošec P Allergy; 2015 May; 70(5):547-55. PubMed ID: 25627309 [TBL] [Abstract][Full Text] [Related]
14. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass. Bozek A; Kolodziejczyk K; Krajewska-Wojtys A; Jarzab J Ann Allergy Asthma Immunol; 2016 Feb; 116(2):156-61. PubMed ID: 26815709 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368 [TBL] [Abstract][Full Text] [Related]
16. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Williams A; Henzgen M; Rajakulasingam K Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):123-6. PubMed ID: 17523386 [TBL] [Abstract][Full Text] [Related]
17. Towards evidence-based medicine in specific grass pollen immunotherapy. Calderon M; Mösges R; Hellmich M; Demoly P Allergy; 2010 Apr; 65(4):420-34. PubMed ID: 20028374 [TBL] [Abstract][Full Text] [Related]
18. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U; Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798 [TBL] [Abstract][Full Text] [Related]
19. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Larenas-Linnemann DE; Pietropaolo-Cienfuegos DR; Calderón MA Ann Allergy Asthma Immunol; 2011 Nov; 107(5):407-416.e11. PubMed ID: 22018611 [TBL] [Abstract][Full Text] [Related]